Sinaptica Therapeutics
- Industry
- Medical Devices
- Founded Year
- 2019
- Headquarters
- Cambridge, Massachusetts, USA
- Employee Count
- 15
Key People
- Anthony Arnold - CEO
- Dr. Alvaro Pascual-Leone - Co-Founder and Chief Medical Officer
- Dr. Peter Bergethon - Co-Founder and Chief Scientific Officer
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in medical technology and neuroscience.
Anthony Arnold, the CEO, has a proven track record in leading medical device companies. Dr. Alvaro Pascual-Leone and Dr. Peter Bergethon bring significant expertise in neuroscience and neuromodulation, positioning the company well for innovation and clinical success.
- Clinical Need
-
Aspect: Very Strong
Summary: There is a significant unmet need for effective Alzheimer's disease treatments, and Sinaptica's approach addresses this gap.
Alzheimer's disease affects millions globally, with limited effective treatments available. Sinaptica's non-invasive neuromodulation therapy offers a promising alternative to current options, potentially improving cognitive functions and quality of life for patients.
- Competition
-
Aspect: Somewhat crowded
Summary: The neuromodulation market has several players, but Sinaptica's focus on Alzheimer's disease provides a unique niche.
The neuromodulation market includes various companies developing devices for neurological conditions. However, Sinaptica's specific focus on Alzheimer's disease differentiates it from competitors, potentially allowing it to capture a unique market segment.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing effective neuromodulation therapies for Alzheimer's disease presents moderate technical challenges.
While neuromodulation is a well-established field, applying it to Alzheimer's disease involves specific challenges, such as targeting appropriate neural pathways and ensuring patient safety. Sinaptica's experienced team is well-equipped to address these challenges.
- Patent
-
Aspect: Strong
Summary: Sinaptica has secured strong patent protection for its SinaptiStim System.
The company's patents cover key aspects of its neuromodulation technology, providing a competitive edge and potential barriers to entry for competitors.
- Financing
-
Aspect: Medium
Summary: Sinaptica has secured funding from reputable investors but may require additional capital for further development.
Investments from Morningside Ventures and the Alzheimer's Drug Discovery Foundation provide a solid financial foundation. However, as the company progresses through clinical trials and commercialization, additional funding will likely be necessary.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The SinaptiStim System has received FDA Breakthrough Device Designation and is progressing through pivotal trials.
The FDA Breakthrough Device Designation facilitates expedited development and review. Successful completion of pivotal trials will be critical for obtaining full regulatory approval and market entry.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 4.9
- Segment CAGR
- 12.5%
- Market Segment
- Neuromodulation Devices
- Market Sub Segment
- Non-Invasive Neuromodulation for Alzheimer's Disease
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.73 |
| 3 | 1.71 |
| 4 | 3.43 |
| 5 | 4.90 |
Key Takeaway
Sinaptica Therapeutics is well-positioned to address the significant unmet need in Alzheimer's treatment with its innovative non-invasive neuromodulation therapy, supported by a strong team and promising market dynamics.